Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to receive our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

Background: Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. Its use in cats has been limited by the absence of pharmacokinetic data. Objective: To determine the pharmacokinetic parameters of oclacitinib in ...

Author(s)
Ferrer, L.; Carrasco, I.; Cristòfol, C.; Puigdemont, A.
Publisher
Wiley, Oxford, UK
Citation
Veterinary Dermatology, 2020, 31, 2, pp 134-e24
Abstract

Background: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to ...

Author(s)
Lopes, N. L.; Campos, D. R.; Machado, M. A.; Alves, M. S. R.; Souza, M. S. G. de; Veiga, C. C. P. da; Merlo, A.; Scott, F. B.; Fernandes, J. I.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Veterinary Research, 2019, 15, 137, pp (8 May 2019)
Abstract

Background: Oclacitinib is a Janus-kinase inhibitor that decreases interleukin-31-induced pruritus in cats. At 0.4-0.6 mg/kg/day orally, it decreased pruritus and skin lesions in <50% of allergic cats. Hypothesis/Objectives: To evaluate efficacy and safety of oclacitinib in feline nonflea nonfood-induced...

Author(s)
Noli, C.; Matricoti, I.; Schievano, C.
Publisher
Wiley, Oxford, UK
Citation
Veterinary Dermatology, 2019, 30, 2, pp 110-e30
Abstract

An 8-year-old male neutered Scottish Fold, whose pruritic dermatitis treated with cyclosporine (CyA), showed chronic gastrointestinal symptoms. Serum chemistry showed a decrease in the A/G ratio and an elevation in the anti-feline coronavirus (FCoV) antibody titer. Based on the test results, FCoV...

Author(s)
Sawa, Y.; Shumoto, G.; Yokoyama, T.; Mitsui, I.; Kaneshima, T.
Publisher
Japanese Society of Veterinary Dermatology, Tokyo, Japan
Citation
Japanese Journal of Veterinary Dermatology, 2020, 26, 1, pp 15-19
Abstract

Pemphigus foliaceus (PF) is the most common autoimmune skin disease in cats. Cats with PF exhibit symmetrical skin lesions most frequently affecting the head and feet. Cats respond rapidly to glucocorticoid monotherapy and in the majority of cases cats achieve remission within a month....

Author(s)
Burrows, A. K.; Siak, M. K.
Publisher
John Wiley & Sons, Chichester, UK
Citation
Advances in veterinary dermatology, Volume 8, 2017, pp 217-219
Abstract

The oclacitinib therapy is used to reduce effect of itching in dogs and cats. In Valerie Fadok's experience, dogs on concurrent immunotherapy have a better response on oclacitinib. Wayne Rosenkrantz stated that oclacitinib has a very rapid onset of activity compared to corticosteroids and that its...

Author(s)
Rosenkrantz, W. S.; Bourgeois, A. S.
Publisher
John Wiley & Sons, Chichester, UK
Citation
Advances in veterinary dermatology, Volume 8, 2017, pp 192-198
Abstract

Background: Oclacitinib is a Janus kinase inhibitor that decreases pruritus and lesions in allergic dogs. In cats, it is able to inhibit interleukin-31-induced pruritus; no information is available on its clinical effectiveness. Hypothesis/Objectives: To evaluate the efficacy, ease of...

Author(s)
Ortalda, C.; Noli, C.; Colombo, S.; Borio, S.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Veterinary Dermatology, 2015, 26, 4, pp 235-e52
Abstract

The aim of this article is to introduce oclacitinib, a new, orally applied Janus-kinase inhibitor, administered to treat canine atopic dermatitis and canine multifactorial pruritus. Atopic dermatitis is a severe, frequently occuring skin disease in dogs. Oclacitinib, licensed in 2014 in Europe, is...

Author(s)
Jerzsele, Á.; Kovács, D.; Somogyi, Z.
Publisher
NAKVI, Budapest, Hungary
Citation
Magyar Állatorvosok Lapja, 2017, 139, 9, pp 545-552
Abstract

Background: Feline allergic skin disease and asthma occur regularly in small animal practice. Objectives: To provide evidence-based recommendations for small animal practitioners on the treatment of feline atopic syndrome (FAS). Methods and materials: The authors reviewed the literature available...

Author(s)
Mueller, R. S.; Nuttall, T.; Prost, C.; Schulz, B.; Bizikova, P.
Publisher
Wiley, Oxford, UK
Citation
Veterinary Dermatology, 2021, 32, 1, pp 43-e8
AbstractFull Text

This study aimed to report the efficacy of oclacitinib on the treatment of feline atopic syndrome (FAS) associated with environmental allergens. A 10-year-old crossbred female cat in Brazil was presented a history of pruritic dermatitis and diarrhoea for 10 months [date not given]. The animal had...

Author(s)
Fernandes, K. S. B. R.; Ferreira, M. B.; Silva, A. M. da; Marques, K. C.; Rocha, B. Z. L. L.; Bezerra, J. A. B.; Filgueira, K. D.
Publisher
Universidade Federal do Rio Grande do Sul, Faculdade de Veterinária, Porto Alegre, Brazil
Citation
Acta Scientiae Veterinariae, 2019, 47, Supplement,

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics